secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2021-08-06T23:59:59+00:00
Accession:  0001564590-21-041896
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara Q2 net loss $13.2M; IMR-687 SCD trial fully enrolled; interim data Q4 2021
--------------------------------------------------------------------------------

- Net loss $13.2M ($0.74/share) vs $10.2M ($0.59) in Q2 2020.
- Cash $66.8M at June 30; $50M July offering extends runway through 2022.
- SCD Phase 2b (Ardent) enrollment complete; primary analysis Q1 2022, interim Q4 2021.
- Beta-thalassemia Phase 2b (Forte) TDT cohort fully enrolled; interim data Q4 2021; NTDT half enrolled.
- Developing HFpEF Phase 2 protocol; FDA interaction planned Q4 2021; Laura Williams appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000156459021041896/0001564590-21-041896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000156459021041896/imra-8k_20210630.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-041896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer